A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema

Andrea L Cheville, Mously Almoza, Janice N. Courmier, Jeffrey R. Basford

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

BACKGROUND: The devastating impact of lymphedema on cancer survivors' quality of life has prompted consideration of several changes in medical and surgical care. Unfortunately, our understanding of the benefits gained from these approaches relative to their cost remains limited. This study was designed to estimate utilities for lymphedema and characterize how utilities differ between subgroups defined by lymphedema etiology and distribution. METHODS: A consecutive sample of 236 subjects with lymphedema seen at a lymphedema clinic completed both a time trade-off (TTO) exercise and the Euroqol 5D. Responses were adjusted in multivariate regression models for demographic factors, comorbidities, and lymphedema severity/location. RESULTS: Most participants (167 of 236, 71%) had lymphedema as a consequence of cancer treatment; 123 with breast cancer and upper extremity involvement. Mean TTO utility estimates were consistently higher than Euroqol 5D estimates. Unadjusted TTO (0.85; standard deviation [SD], 0.21) and Euroqol 5D (0.76; SD, 0.18) scores diminished with increasing lymphedema stage and patient body mass index (BMI). Adjusted utility scores were lowest in patients with cancer-related lower extremity lymphedema (TTO=0.82; SD, 0.04 and Euroqol 5D=0.80; SD, 0.03). Breast cancer patients also had lower adjusted Euroqol 5D scores (0.80; SD, 0.02). CONCLUSIONS: Lymphedema-associated utilities are in the range of 0.80. Lower utilities are observed for patients with higher lymphedema stages, elevated BMI, and cancer-related lymphedema. Greater expenditures for the prevention and treatment of cancer-related lymphedema are warranted.

Original languageEnglish (US)
Pages (from-to)3722-3731
Number of pages10
JournalCancer
Volume116
Issue number15
DOIs
StatePublished - Aug 1 2010

Fingerprint

Lymphedema
Cohort Studies
Prospective Studies
Neoplasms
Body Mass Index
Breast Neoplasms
Second Primary Neoplasms
Health Expenditures
Upper Extremity
Survivors
Comorbidity
Lower Extremity

Keywords

  • Body mass index
  • Cost
  • Health utilities
  • Lymphedema
  • Quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema. / Cheville, Andrea L; Almoza, Mously; Courmier, Janice N.; Basford, Jeffrey R.

In: Cancer, Vol. 116, No. 15, 01.08.2010, p. 3722-3731.

Research output: Contribution to journalArticle

Cheville, Andrea L ; Almoza, Mously ; Courmier, Janice N. ; Basford, Jeffrey R. / A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema. In: Cancer. 2010 ; Vol. 116, No. 15. pp. 3722-3731.
@article{a5ea34d9a42b41c9b74d33d1de434d7c,
title = "A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema",
abstract = "BACKGROUND: The devastating impact of lymphedema on cancer survivors' quality of life has prompted consideration of several changes in medical and surgical care. Unfortunately, our understanding of the benefits gained from these approaches relative to their cost remains limited. This study was designed to estimate utilities for lymphedema and characterize how utilities differ between subgroups defined by lymphedema etiology and distribution. METHODS: A consecutive sample of 236 subjects with lymphedema seen at a lymphedema clinic completed both a time trade-off (TTO) exercise and the Euroqol 5D. Responses were adjusted in multivariate regression models for demographic factors, comorbidities, and lymphedema severity/location. RESULTS: Most participants (167 of 236, 71{\%}) had lymphedema as a consequence of cancer treatment; 123 with breast cancer and upper extremity involvement. Mean TTO utility estimates were consistently higher than Euroqol 5D estimates. Unadjusted TTO (0.85; standard deviation [SD], 0.21) and Euroqol 5D (0.76; SD, 0.18) scores diminished with increasing lymphedema stage and patient body mass index (BMI). Adjusted utility scores were lowest in patients with cancer-related lower extremity lymphedema (TTO=0.82; SD, 0.04 and Euroqol 5D=0.80; SD, 0.03). Breast cancer patients also had lower adjusted Euroqol 5D scores (0.80; SD, 0.02). CONCLUSIONS: Lymphedema-associated utilities are in the range of 0.80. Lower utilities are observed for patients with higher lymphedema stages, elevated BMI, and cancer-related lymphedema. Greater expenditures for the prevention and treatment of cancer-related lymphedema are warranted.",
keywords = "Body mass index, Cost, Health utilities, Lymphedema, Quality of life",
author = "Cheville, {Andrea L} and Mously Almoza and Courmier, {Janice N.} and Basford, {Jeffrey R.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1002/cncr.25068",
language = "English (US)",
volume = "116",
pages = "3722--3731",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

TY - JOUR

T1 - A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema

AU - Cheville, Andrea L

AU - Almoza, Mously

AU - Courmier, Janice N.

AU - Basford, Jeffrey R.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - BACKGROUND: The devastating impact of lymphedema on cancer survivors' quality of life has prompted consideration of several changes in medical and surgical care. Unfortunately, our understanding of the benefits gained from these approaches relative to their cost remains limited. This study was designed to estimate utilities for lymphedema and characterize how utilities differ between subgroups defined by lymphedema etiology and distribution. METHODS: A consecutive sample of 236 subjects with lymphedema seen at a lymphedema clinic completed both a time trade-off (TTO) exercise and the Euroqol 5D. Responses were adjusted in multivariate regression models for demographic factors, comorbidities, and lymphedema severity/location. RESULTS: Most participants (167 of 236, 71%) had lymphedema as a consequence of cancer treatment; 123 with breast cancer and upper extremity involvement. Mean TTO utility estimates were consistently higher than Euroqol 5D estimates. Unadjusted TTO (0.85; standard deviation [SD], 0.21) and Euroqol 5D (0.76; SD, 0.18) scores diminished with increasing lymphedema stage and patient body mass index (BMI). Adjusted utility scores were lowest in patients with cancer-related lower extremity lymphedema (TTO=0.82; SD, 0.04 and Euroqol 5D=0.80; SD, 0.03). Breast cancer patients also had lower adjusted Euroqol 5D scores (0.80; SD, 0.02). CONCLUSIONS: Lymphedema-associated utilities are in the range of 0.80. Lower utilities are observed for patients with higher lymphedema stages, elevated BMI, and cancer-related lymphedema. Greater expenditures for the prevention and treatment of cancer-related lymphedema are warranted.

AB - BACKGROUND: The devastating impact of lymphedema on cancer survivors' quality of life has prompted consideration of several changes in medical and surgical care. Unfortunately, our understanding of the benefits gained from these approaches relative to their cost remains limited. This study was designed to estimate utilities for lymphedema and characterize how utilities differ between subgroups defined by lymphedema etiology and distribution. METHODS: A consecutive sample of 236 subjects with lymphedema seen at a lymphedema clinic completed both a time trade-off (TTO) exercise and the Euroqol 5D. Responses were adjusted in multivariate regression models for demographic factors, comorbidities, and lymphedema severity/location. RESULTS: Most participants (167 of 236, 71%) had lymphedema as a consequence of cancer treatment; 123 with breast cancer and upper extremity involvement. Mean TTO utility estimates were consistently higher than Euroqol 5D estimates. Unadjusted TTO (0.85; standard deviation [SD], 0.21) and Euroqol 5D (0.76; SD, 0.18) scores diminished with increasing lymphedema stage and patient body mass index (BMI). Adjusted utility scores were lowest in patients with cancer-related lower extremity lymphedema (TTO=0.82; SD, 0.04 and Euroqol 5D=0.80; SD, 0.03). Breast cancer patients also had lower adjusted Euroqol 5D scores (0.80; SD, 0.02). CONCLUSIONS: Lymphedema-associated utilities are in the range of 0.80. Lower utilities are observed for patients with higher lymphedema stages, elevated BMI, and cancer-related lymphedema. Greater expenditures for the prevention and treatment of cancer-related lymphedema are warranted.

KW - Body mass index

KW - Cost

KW - Health utilities

KW - Lymphedema

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=77955406161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955406161&partnerID=8YFLogxK

U2 - 10.1002/cncr.25068

DO - 10.1002/cncr.25068

M3 - Article

C2 - 20564063

AN - SCOPUS:77955406161

VL - 116

SP - 3722

EP - 3731

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 15

ER -